Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04483778
Other study ID # STRIvE-02
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date July 13, 2020
Est. completion date December 2040

Study information

Verified date April 2024
Source Seattle Children's Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase I, open-label, non-randomized study that will enroll pediatric and young adult research participants with relapsed or refractory non-CNS solid tumors to evaluate the safety, feasibility, and efficacy of administering T cell products derived from the research participant's blood that have been genetically modified to express a B7H3-specific receptor (chimeric antigen receptor, or CAR) that will target and kill solid tumors that express B7H3. On Arm A of the study, research participants will receive B7H3-specific CAR T cells only. On Arm B of the study, research participants will receive CAR T cells directed at B7H3 and CD19, a marker on the surface of B lymphocytes, following the hypothesis that CD19+ B cells serving in their normal role as antigen presenting cells to T cells will promote the expansion and persistence of the CAR T cells. Arm A CAR T cells include the protein EGFRt and Arm B CAR T cells include the protein HER2tG. These proteins can be used to both track and destroy the CAR T cells in case of undue toxicity. The primary objectives of the study will be to determine the feasibility of manufacturing the cell products, the safety of the T cell product infusion, to determine the maximum tolerated dose of the CAR T cells products, to describe the full toxicity profile of each product, and determine the persistence of the modified cell in the participant's body on each arm. Participants will receive a single dose of T cells comprised of two different subtypes of T cells (CD4 and CD8 T cells) felt to benefit one another once administered to the research participants for improved potential therapeutic effect. The secondary objectives of this protocol are to study the number of modified cells in the patients and the duration they continue to be at detectable levels. The investigators will also quantitate anti-tumor efficacy on each arm. Participants who experience significant and potentially life-threatening toxicities (other than clinically manageable toxicities related to T cells working, called cytokine release syndrome) will receive infusions of cetuximab (an antibody commercially available that targets EGFRt) or trastuzumab (an antibody commercially available that targets HER2tG) to assess the ability of the EGFRt on the T cells to be an effective suicide mechanism for the elimination of the transferred T cell products.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 68
Est. completion date December 2040
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 0 Years to 26 Years
Eligibility Inclusion Criteria: - Participants age = 26 years at the time of consent for study participation; the first 2 participants enrolled and treated with CAR T cells in both Arms A and B will be = 15 years. and = 26 years at time of consent for study participation - Histologically diagnosed malignant, non-primary CNS solid tumor - Evidence of refractory or recurrent disease - Lansky or Karnofsky score = 50 - Life expectancy = 8 weeks - Recovered from significant acute toxic effects of all prior chemotherapy, immunotherapy and radiotherapy - If no apheresis product or usable T cell product is available, all chemotherapy has been discontinued = 7 days prior to enrollment - If no apheresis or usable T cell product is available, all biologic therapy has been discontinued = 7 days prior to enrollment - If no apheresis product or T cell product is available, all systemic corticosteroid therapy has been discontinued = 7 days prior to enrollment (physiologic replacement dosing is allowed) - If no apheresis product or usable T cell product is available, at least 3 half-lives or 30 days (whichever is shorter) from time of last dose of anti-tumor directed antibody therapy (including checkpoint inhibitor) at time of enrollment - If no apheresis product or usable T cell product is available, at least 6 weeks post last dose of myeloablative therapy and autologous and/or allogeneic stem cell transplant, or non-myeloablative therapy and allogeneic stem cell transplant (all timed from stem cell infusion). Participants who receive autologous stem cell infusion following non-myeloablative therapy are eligible once all other eligibility requirements are met. - If no apheresis product or usable T cell product is available, participants who have received genetically modified cell therapy must be at least 30 days from most recent cell infusion prior to enrollment - If no apheresis product or usable T cell product is available, participants with neuroblastoma must be at least 12 weeks from I131 MIBG therapy. - Adequate organ function - Adequate laboratory values - Participant is able to tolerate apheresis (including placement of temporary apheresis catheter, if necessary), or already has an apheresis product available for use in manufacturing. - Participants of childbearing potential must agree to use highly effective contraception Exclusion Criteria: - Presence of active malignancy other than primary malignant solid tumor diagnosis - Current relevant CNS pathology - Receiving external beam radiation therapy at time of enrollment - Presence of active GVHD, or receiving immunosuppressive therapy for treatment or prevention of GVHD within 4 weeks prior to enrollment - Participant is pregnant or breastfeeding - Participant has presence of active severe infection - Participant has presence of any condition that, in the option of an investigator, would prohibit the participant from undergoing treatment under this protocol - Participant has primary immunodeficiency syndrome - Unwilling or unable to provide consent/assent for participation in the study and 15 year follow up period

Study Design


Related Conditions & MeSH terms

  • Carcinoma
  • Clear Cell Sarcoma
  • Desmoplastic Small Round Cell Tumor
  • Ewing Sarcoma
  • Germ Cell Tumor
  • Hepatoblastoma
  • Malignant Peripheral Nerve Sheath Tumors
  • Melanoma
  • Neoplasms
  • Nerve Sheath Neoplasms
  • Neuroblastoma
  • Osteosarcoma
  • Pediatric Solid Tumor
  • Retinoblastoma
  • Rhabdoid Tumor
  • Rhabdomyosarcoma
  • Sarcoma
  • Sarcoma, Clear Cell
  • Sarcoma, Ewing
  • Sarcoma, Synovial
  • Soft Tissue Sarcoma
  • Synovial Sarcoma
  • Wilms Tumor

Intervention

Biological:
second generation 4-1BB? B7H3-EGFRt-DHFR
Autologous CD4+ and CD8+ T-cells lentivirally transduced to express a second generation 4-1BB? B7H3-EGFRt-DHFR
second generation 4-1BB? B7H3-EGFRt-DHFR(selected) and a second generation 4-1BB? CD19-Her2tG
Autologous CD4+ and CD8+ T-cells lentivirally transduced to express a second generation 4-1BB? B7H3-EGFRt-DHFR(selected) and a second generation 4-1BB? CD19-Her2tG
Drug:
Pembrolizumab
SCRI-CARB7H3(s)x19 plus pembrolizumab

Locations

Country Name City State
United States Seattle Children's Hospital Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
Seattle Children's Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Evaluate for the presence of B7H3 CAR T cells in tumor tissue and/or normal tissue if a tissue biopsy, tumor biopsy, or resection is clinically indicated post-treatment Tumor tissue, when obtained, will be assessed for the presence of adoptively transferred CAR T cells 84 days
Other Evaluate B7H3 antigen expression in tumor tissue and/or normal tissue if a tissue biopsy, tumor biopsy, or resection is available Tumor tissue, when obtained, will be assessed for the presence of B7H3 antigen 84 days
Other Analyze blood, bone marrow, CSF, normal tissue, and/or tumor tissue for biomarkers of safety and/or anti-tumor activity If a tissue biopsy, tumor biopsy, or resection is clinically indicated post-treatment, pathology will be assessed for the presence of B7H3 CAR T cells 84 days
Other Assess the efficacy of infusional cetuximab and/or trastuzumab in ablating transferred T cells and ameliorating acute toxicities in treated participants Biologic specimens, when obtained, will be assessed for biomarkers of safety and/or anti-tumor efficacy 84 days
Primary Assess the safety and tolerability of cellular immunotherapy utilizing ex-vivo expanded autologous T cells genetically modified to express B7H3-specific CAR (Arm A) Type, frequency, severity, and duration of adverse events will be tabulated and summarized 28 days
Primary Assess the safety and tolerability of cellular immunotherapy utilizing ex-vivo expanded autologous T cells genetically modified to express a bispecific B7H3xCD19 CAR (Arm B) Type, frequency, severity, and duration of adverse events will be tabulated and summarized 28 days
Primary To assess the safety and tolerability of cellular immunotherapy utilizing ex-vivo expanded autologous T cells genetically modified to express a bispecific B7H3xCD19 CAR given in combination with pembrolizumab (Arm C) Type, frequency, severity, and duration of adverse events will be tabulated and summarized to determine maximal tolerated dose 28 days
Primary To determine the maximum tolerated dose (MTD) of B7H3-specific CAR (Arm A) Type, frequency, severity, and duration of adverse events will be tabulated and summarized to determine maximal tolerated dose 28 days
Primary To determine the maximum tolerated dose of bispecific B7H3xCD19 CAR (Arm B) Type, frequency, severity, and duration of adverse events will be tabulated and summarized 28 days
Primary To determine the feasibility of administration of pembrolizumab in combination with bispecific B7H3xCD19 CAR (Arm C) Type, frequency, severity, and duration of adverse events will be tabulated and summarized 28 days
Primary To assess the dose limiting toxicities (DLTs) and describe the full toxicity profile for each study arm Type, frequency, severity, and duration of adverse events will be tabulated and summarized 28 days
Primary To assess the feasibility of manufacturing B7H3 specific CARs from patient-derived lymphocytes Type, frequency, severity, and duration of adverse events will be tabulated and summarized 28 days
Primary To assess the feasibility of manufacturing B7H3xCD19 bispecific CARs from patient-derived lymphocytes Type, frequency, severity, and duration of adverse events will be tabulated and summarized 28 days
Secondary Determine the duration of in vivo persistence of adoptively transferred T cells in the peripheral blood and compare engraftment between T cell products and treatment arms Presence of CAR T cells in the peripheral blood will be assessed 84 days
Secondary Determine the magnitude of in vivo persistence of adoptively transferred T cells in the peripheral blood and compare engraftment between T cell products Number of CAR T cells in the peripheral blood will be assessed 84 days
Secondary Quantitate anti-tumor responses by measuring changes in tumor burden using disease-specific evaluations Presence of CAR T cells in the peripheral blood will be assessed 84 days
Secondary Describe the relative expansion and persistence of the CAR T cell product and retention of function for B7H3xCD19 bispecific CARs determined by maintenance of B cell aplasia (BCA) with and without pembrolizumab Presence of CAR T cells in the peripheral blood will be assessed 84 days
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT03979872 - Risk Information and Skin-cancer Education for Undergraduate Prevention N/A
Recruiting NCT04986748 - Using QPOP to Predict Treatment for Sarcomas and Melanomas
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Recruiting NCT05707286 - Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
Active, not recruiting NCT05470283 - Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma Phase 1
Recruiting NCT05077137 - A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy Phase 1
Active, not recruiting NCT02721459 - XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma Phase 1
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Recruiting NCT05839912 - Excision of Lymph Node Trial (EXCILYNT) (Mel69) N/A
Recruiting NCT04971499 - A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma Phase 1/Phase 2
Recruiting NCT05263453 - HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation Phase 2
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06413680 - A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies Phase 1/Phase 2
Completed NCT03348891 - TNF in Melanoma Patients Treated With Immunotherapy N/A
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03171064 - Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment Phase 2
Not yet recruiting NCT05539118 - Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma Phase 1/Phase 2
Recruiting NCT05171374 - pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
Withdrawn NCT02854488 - Yervoy Pregnancy Surveillance Study